A case of essential thrombocytosis developing nephrotic syndrome and severe endothelial damage

Journal of Nephrology

Volumn 19, Issue 5, 2006, Pages 656-659

  Saigusa, Takamitsu ^a   Kikuchi, Yuichi ^a   Yamada, Muneharu ^a   Imakiire, Toshihiko ^a   Hyodo, Toshitake ^a   Suzuki, Shigenobu ^a   Miura, Soichiro ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Endothelial damage; Essential thrombocytosis; Myeloproliferative disease; Nephrotic syndrome; Platelet derived growth factor receptor (PDGFR )

Indexed keywords

BICALUTAMIDE; CARBOQUONE; HYDROXYUREA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISOLONE;

AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CASE REPORT; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; ENDOTHELIAL DYSFUNCTION; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; KIDNEY BIOPSY; MALE; MEGAKARYOCYTE; MESANGIUM; NEPHROTIC SYNDROME; PROLIFERATIVE GLOMERULONEPHRITIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEINURIA; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTOSIS; URINALYSIS;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; BLOOD PLATELETS; CELL PROLIFERATION; ENDOTHELIUM; GLOMERULAR BASEMENT MEMBRANE; GLOMERULAR MESANGIUM; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; JAPAN; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MYELOPROLIFERATIVE DISORDERS; PLATELET ACTIVATION; PLATELET COUNT; PLATELET-DERIVED GROWTH FACTOR; PROTEINURIA; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SYNDROME; THROMBOCYTOSIS; TIME FACTORS;

EID: 33947227762     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Au WY, Chan KW, Lui SL, Lam CC, Kwong YL. Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. Am J Kidney Dis 1999; 34: 889-93.
2. Read NG, Astbury PJ, Evans GO, Goodwin DA, Rowlands A. Nephrotic syndrome associated with N-hydroxyureas, inhibitors of 5-lipoxygenase. Arch Toxicol 1995; 69: 480-90.
3. Morley TJ, Evans GO, Goodwin DA, Read NG, Hodgson ST, Hawksworth GM. Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome. Toxicol Appl Pharmacol 1997; 146: 299-308.
4. Briere J, Kiladjian JJ, Peynaud-Debayle E. Megakaryocytes and platelets in myeloproliferative disorders. Baillieres Clin Haematol 1997; 10: 65-88.
5. Zeigler FC, de Sauvage F, Widmer HR, Keller GA, Donahue C, Schreiber RD, Malloy B, Hass P, Eaton D, Matthews W. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994; 84: 4045-52.
6. Couser WG, Johnson RJ. Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994; 23: 193-8.
7. Stein-Oakley AN, Maguire JA, Dowling J, Perry G, Thomsom NM. Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. Kidney Int 1997; 51: 195-204.
8. Randi ML, Meneghin C, Zerbinati P, Sbarai A, Rampin E, Pasini R, Zanin L, Girolami A, Cella G. Soluble plasma thrombomodulin levels in patients with chronic myeloproliferative disorder. Clin Appl Thromb Hemost 1999; 5: 43-7.
9. Sirolli V, Ballone E, Garofalo D, Merciaro G, Settefrati N, Di Mascio R, Di Gregorio P, Bonomini M. Platelet activation markers in patients with nephrotic syndrome: a comparative study of different platelet function tests. Nephron 2002; 91: 424-30.